KALAMAZOO, Mich. – The National Institute of Allergy and Infectious Diseases (NIAID), an institute within the National Institutes of Health (NIH), has awarded a nearly $3 million small Business Technology Transfer Research (STTR) grant to NanoVir, LLC to support synthesis and pre-clinical development of lead antiviral compounds for treatment of human papillomavirus 16 (HPV16).

KALAMAZOO, Mich. - Dr. Chris Fisher, co-founder of NanoVir, LLC and the company's Director of Biology, has been invited to speak on November 4, 2007 at the 24th International Papillomavirus Conference and Clinical Workshop in Beijing, China. The Workshop will run November 3-9, 2007.